gene editing

Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Motley Fool
Celgene
Editas Medicine
Juno Therapeutics
CRISPR
gene editing
Flag link:
More CRISPR Stock Catalysts Ahead
More CRISPR Stock Catalysts Ahead
Motley Fool
gene editing
CRISPR
Editas Medicine
Intellia Therapeutics
CRISPR Therapeutics
Flag link:
Cellectis gene editing patent upheld in Europe
Cellectis gene editing patent upheld in Europe
Seeking Alpha
gene editing
Europe
Cellectis
patents
Flag link:
Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug
Biotech Stock Pops On Promising First In-Human CRISPR Gene-Editing Drug
Investors Business Daily
CRISPR Therapeutics
gene editing
CRISPR
beta thalassemia
sickle cell disease
Flag link:
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Endpoints
Editas Medicine
Celgene
Juno Therapeutics
CRISPR
gene editing
immunotherapy
Flag link:
A Look at America’s First CRISPR Clinical Trial
A Look at America’s First CRISPR Clinical Trial
Xtalks
CRISPR
gene editing
clinical trials
Flag link:
First use of CRISPR against cancer in patients clears early safety hurdles
First use of CRISPR against cancer in patients clears early safety hurdles
Stat
gene editing
CRISPR
patient safety
cancer
Flag link:
A deal-hungry Vertex ushers in three more gene editing programs as it closes out harbinger CRISPR deal
A deal-hungry Vertex ushers in three more gene editing programs as it closes out harbinger CRISPR deal
Endpoints
Vertex Pharmaceuticals
CRISPR
gene editing
CTX001
Flag link:
Why Novo Nordisk should buy Uniqure
Why Novo Nordisk should buy Uniqure
EP Vantage
Novo Nordisk
gene editing
hemophilia
uniQure
Bluebird Bio
Flag link:
Novo taps bluebird bio for gene-editing tech
Novo taps bluebird bio for gene-editing tech
Fierce Biotech
Novo Nordisk
Bluebird Bio
R&D
gene editing
hemophilia
Flag link:
3 Reasons Vertex Pharmaceuticals Is Poised for a Big Year
3 Reasons Vertex Pharmaceuticals Is Poised for a Big Year
Motley Fool
Vertex Pharmaceuticals
cystic fibrosis
gene editing
Flag link:
Gene-Editing Company Beam Seeks $100 Million IPO
Gene-Editing Company Beam Seeks $100 Million IPO
BioSpace
Beam Therapeutics
IPOs
gene editing
Flag link:
Can Synthetic Biology Make Insulin Faster, Better and Cheaper?
Can Synthetic Biology Make Insulin Faster, Better and Cheaper?
Forbes
diabetes
insulin
drug pricing
Genentech
gene editing
Flag link:
CRISPR Gene-Editing May Offer Path To Cure For HIV, First Published Report Shows
CRISPR Gene-Editing May Offer Path To Cure For HIV, First Published Report Shows
NPR
HIV
CRISPR
gene editing
Flag link:
Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System
Challenging CRISPR, Trucode Raises $34M for New Gene-Editing System
Xconomy
Trucode
gene editing
CRISPR
Flag link:
WHO Launches Registry for Gene Editing Studies
WHO Launches Registry for Gene Editing Studies
RAPS.org
WHO
gene editing
Flag link:
Cadre of gene-editing biotechs rally against altering DNA that could affect future generations
Cadre of gene-editing biotechs rally against altering DNA that could affect future generations
Endpoints
biotech
gene editing
Alliance for Regenerative Medicine
ethics
Flag link:
CRISPR slows the growth of triple-negative breast cancer in mice
CRISPR slows the growth of triple-negative breast cancer in mice
Fierce Biotech
Boston Children's Hospital
CRISPR
gene editing
Lipocalin 2
triple negative breast cancer
Flag link:
A CRISPR alternative for editing genes without cutting
A CRISPR alternative for editing genes without cutting
Fierce Biotech
gene editing
CRISPR
Columbia University
INTEGRATE
Flag link:
GSK partners with CRISPR pioneer Doudna to search for new drugs
GSK partners with CRISPR pioneer Doudna to search for new drugs
Stat
GSK
CRISPR
Doudna
gene editing
drug discovery
Flag link:

Pages